Merck: Keytruda Combo Improves Survival In Her2-Positive Gastric Cancer -ESMO
Merck & Co. announced that KEYTRUDA® with Trastuzumab and Chemotherapy improves survival in HER2-positive gastric cancer patients compared to Trastuzumab and Chemotherapy alone. Visit their website for details.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
